Early Administration of Anti–SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients

Mostrar otras versiones (1)

INTRODUCTION: Kidney transplant recipients (KTRs) are prone to develop severe COVID-19 and are less well protected by vaccine than immunocompetent subjects. Thus, the use of neutralizing anti–SARS-CoV-2 monoclonal antibody (MoAb) to confer a passive immunity appears attractive in KTRs. METHODS: We p...

Descripción completa

Detalles Bibliográficos
Autores principales: Gueguen, Juliette, Colosio, Charlotte, Del Bello, Arnaud, Scemla, Anne, N’Guyen, Yohan, Rouzaud, Claire, Carvalho-Schneider, Claudia, Gautier Vargas, Gabriela, Tremolières, Pierre, Eddine, A. Jalal, Masset, Christophe, Thaunat, Olivier, Chabannes, Melchior, Malvezzi, Paulo, Pommerolle, Pierre, Couzi, Lionel, Kamar, Nassim, Caillard, Sophie, Gatault, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957354/
https://www.ncbi.nlm.nih.gov/pubmed/35372734
http://dx.doi.org/10.1016/j.ekir.2022.03.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957354/
https://www.ncbi.nlm.nih.gov/pubmed/35372734
http://dx.doi.org/10.1016/j.ekir.2022.03.020

Ejemplares similares